QC
FOLD

Quadrature Capital’s Amicus Therapeutics FOLD Stock Holding History

Quadrature Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,512
Closed -$255K – 1186
2025
Q2 		$255K Buy
+44,512
New +$287K ﹤0.01% 739

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Quadrature Capital's FOLD Position: Q3 2025 in Review

Quadrature Capital sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 44,512 shares — an estimated $255K sold.

Quadrature Capital first reported a position in FOLD in Q2 2025 and held it in 1 quarter. The position peaked at $255K in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Quadrature Capital reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 44,512 Amicus Therapeutics shares in Q3 2025, an estimated $255K.
  • Quadrature Capital first reported a position in Amicus Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quadrature Capital's Amicus Therapeutics position peaked at $255K in Q2 2025.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.